Catégorie : Cannabis et Réduction des Risques

US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws 1991-1992 to 2012-2013, Deborah S. Hasin et al., 2017

US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws 1991-1992 to 2012-2013 Deborah S. Hasin, Aaron L. Sarvet, Magdalena Cerda, Katherine M. Keyes, Malka Stohl, Sandro Galea, Melanie M. Wall JAMA Psychiatry, 2017, 74, (6), 579–610. Doi: 10.1001/jamapsychiatry.2017.0724 PMCID: PMC5539836      PMID: 28445557 Key Points Question Are US state medical marijuana laws one of the underlying factors for increases in risk for adult cannabis use and cannabis use disorders seen since the early 1990s? Findings In this analysis using US national survey data collected in 1991-1992, 2001-2002, and 2012-2013 from 118 497 participants, the risk for cannabis use and cannabis use disorders increased at a significantly greater [...]

Lire la suite

Cannabis use, pain and prescription opioid use in people living with chronic non-cancer pain : Findings from a four-year prospective cohort, Gabrielle Campbell et al., 2018

Cannabis use, pain and prescription opioid use in people living with chronic non-cancer pain : Findings from a four-year prospective cohort Gabrielle Campbell, Wayne D. Hall, Amy Peacock, Nicholas Lintzeris, Raimondo Bruno, Briony Larance, Suzanne Nielsen, Milton Cohen, Gary Chan, Richard P. Mattick, Fiona Blyth, Marian Shanahan, Timothy Dobbins, Michael Farrell, Louisa Degenhardt Lancet Public Health, 2018, 3, (7): e341–e350. doi:10.1016/S2468-2667(18)30110-5.   Abstract Background : There has been growing interest in the use of cannabis and cannabinoids to treat chronic non-cancer pain (CNCP). Cannabis and cannabinoids have attracted attention because of their greater safety compared with opioids, and the possibility that their use can reduce opioid [...]

Lire la suite

The effect of cannabis laws on opioid use, J.L. Flexon et al., 2019

The effect of cannabis laws on opioid use. J.L. Flexon, L. Stolzenberg, S.J. d'Alessio International Journal of Drug Policy, 2019, 74, 152-159. doi : 10.1016/j.drugpo.2019.09.013. Abstract BACKGROUND : Many Americans rely on opioids at varying dosages to help ameliorate their suffering. However, empirical evidence is mounting that opioids are ineffective at controlling non-cancer related chronic pain, and many argue the strategies meant to relieve patient suffering are contributing to the growing opioid epidemic. Concurrently, several states now allow the use of medical cannabis to treat a variety of medical conditions, including chronic pain. Needing more exploration is the impact of cannabis laws on general opioid reliance [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, novembre 2019

Bibliographie : Cannabis et Cannabinoides en Psychiatrie Docteur Christian Sueur, GRECC, novembre 2019.   Cannabinoïdes et Anxiété Cannabinoïdes et psychose Cannabinoïdes et dépression   Cannabinoides et PTSD : cf la Bibliographie : Cannabinoïdes et PTSD https://www.grecc.org/publications/bibliographies/bibliographie-cannabinoides-et-ptsd-docteur-christian-sueur-grecc-2019/ Cannabinoides et Addictions : cf Bibliographie : Substances psychédéliques et Cannabinoïdes, et traitements des Addictions https://www.grecc.org/publications/bibliographies/bibliographie-substances-psychedeliques-et-cannabinoides-et-traitement-des-addictions-dr-christian-sueur-grecc-octobre-2019/

Lire la suite

Notes from the Field : Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol — Utah, 2017–2018, Roberta Z. Horth et al., 2019

Notes from the Field : Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol — Utah, 2017–2018 Roberta Z. Horth, Barbara Crouch, B. Zane Horowitz, Amelia Prebish, Matthew Slawson,  Jennifer McNair, Chris Elsholz, Stephen Gilley, Jenny Robertson, Ilene Risk, Mary Hill, Linnea Fletcher, Wei Hou, Dallin Peterson, Karlee Adams, Dagmar Vitek, Allyn Nakashima, Angela Dunn MMWR / May 25, 2018 / Vol. 67 / No. 20 US Department of Health and Human Services/Centers for Disease Control and Prevention   On December 8, 2017, the Utah Poison Control Center (UPCC) notified the Utah Department of Health (UDOH) of reports of emergency department visits associated with reported [...]

Lire la suite

Psychiatric Comorbidity of Cannabis Use Disorder, David Gorelick, 2019

Psychiatric Comorbidity of Cannabis Use Disorder David Gorelick In book : "Cannabis Use Disorders", January 2019 DOI : 10.1007/978-3-319-90365-1_13   Abstract : Objective : This chapter reviews the epidemiology and treatment of cannabis use disorder (CUD) with psychiatric comorbidity. Methods : We summarize the findings of English-language epidemiological studies reporting current (past-year) comorbidity and of controlled clinical trials of treatment in which the majority of participants had diagnosed CUD and a specific comorbid disorder. Results : There is substantial CUD comorbidity among community-dwelling adults with major psychiatric disorders: 4–6% for depression, 14% for bipolar disorder, 5% for anxiety disorder, and 16% for schizophrenia. Conversely, there is substantial psychiatric [...]

Lire la suite

Opportunities for cannabis in supportive care in cancer, Amber S. Kleckner et al., 2019

Opportunities for cannabis in supportive care in cancer Amber S. Kleckner , Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, Michelle C. Janelsins, Gary R. Morrow and Luke J. Peppone Therapeutic Advances in Medical Oncology, 2019, Vol. 11, 1–29 DOI: 10.1177/1758835919866362   Abstract Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symptoms in patients with cancer poses a challenge to clinicians in discussing this option with their patients. A review was [...]

Lire la suite

Legal highs : staying on top of the flood of novel psychoactive substances, David Baumeister et al., 2015

Legal highs : staying on top of the flood of novel psychoactive substances David Baumeister, Luis M. Tojo and Derek K. Tracy Therapeutic Advances in Psychopharmacology, 2015, Vol. 5, (2), 97–132 DOI: 10.1177/2045125314559539   Abstract : There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called ‘legal highs’, which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown chemists and laboratories are producing new, and as yet nonproscribed, compounds for human consumption; and as soon as they are banned, which they inevitably are, slightly modified analogues are produced to [...]

Lire la suite

A National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017, Hongying Dai & Kimber P. Richter, 2019

A National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017 Hongying Dai, Kimber P. Richter JAMA Network Open, 2019, 2, (9), e1911936. doi:10.1001/jamanetworkopen.2019.11936   Abstract IMPORTANCE : The number of states legalizing marijuana for medical and recreational use is increasing. Little is known regarding how or why adults with medical conditions use it. OBJECTIVES : To report the prevalence and patterns of marijuana use among adults with and without medical conditions, overall and by sociodemographic group, and to further examine the associations between current marijuana use and the types and number of medical conditions. DESIGN, SETTING, AND PARTICIPANTS : This survey study used a probability [...]

Lire la suite